FLUBLOK Drug Profile

Summary for Tradename: FLUBLOK

High Confidence Patents:	2
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for FLUBLOK Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for FLUBLOK Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Protein Sciences Corporation	FLUBLOK	influenza vaccine	Injection	125285		2036-06-23	DrugPatentWatch analysis and company disclosures
Protein Sciences Corporation	FLUBLOK	influenza vaccine	Injection	125285		2015-06-09	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for FLUBLOK Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Protein Sciences Corporation	FLUBLOK	influenza vaccine	Injection	125285		2036-10-12	Patent claims search
Protein Sciences Corporation	FLUBLOK	influenza vaccine	Injection	125285		2034-01-23	Patent claims search
Protein Sciences Corporation	FLUBLOK	influenza vaccine	Injection	125285		2034-09-23	Patent claims search

International Patents for FLUBLOK

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2016210093
European Patent Office	3313438
Canada	2990635

Market Dynamics and Financial Trajectory for Flublok

Last updated: April 17, 2026

What is the current market position of Flublok?

Flublok, a recombinant hemagglutinin-based influenza vaccine developed by Protein Sciences (acquired by Sanofi in 2017), is positioned as an alternative to traditional egg-based flu vaccines. Approved by the FDA in 2013 for adults aged 18 and older, Flublok offers a cell-culture produced vaccine with a recombinant protein platform, reducing the risk of allergic reactions linked to egg proteins.

How does Flublok differentiate within the influenza vaccine market?

Flublok's key competitive advantages include:

• Egg-free production process: Suitable for individuals with egg allergies.
• Higher efficacy potential: Clinical trials demonstrate comparable or superior immune responses than egg-based vaccines.
• Faster manufacturing: Capable of rapid production cycles, advantageous during emergent influenza strains or pandemics.

The market's reliance on traditional egg-based vaccines remains dominant. However, Flublok occupies a niche, especially among high-risk populations seeking non-egg vaccines.

What is the current global market size for influenza vaccines?

The global influenza vaccine market was valued at approximately USD 4.5 billion in 2021 and is projected to grow at a CAGR of 7% through 2027, reaching nearly USD 7 billion. Key drivers include:

• Increasing influenza vaccination coverage
• Expanding government immunization programs
• Growing awareness of egg allergy safety

Major competitors include GlaxoSmithKline (Fluarix, Flulaval), Sanofi (Vaxigrip), and Seqirus (Afluria). Flublok holds an estimated 1-2% of this market, primarily in the U.S.

What are pharmacoeconomic factors affecting Flublok’s market penetration?

Flublok’s price point is higher (~USD 35-50 per dose) compared to traditional vaccines (~USD 15-25). Factors influencing its market share include:

• Cost-effectiveness for high-risk groups: Particularly for individuals with egg allergies or immunocompromised status.
• Insurance reimbursement policies: Coverage varies, impacting patient access.
• Physician awareness: Limited familiarity with recombinant vaccines constrains adoption.

Investments in educational campaigns and insurance negotiations could enhance uptake.

What are regulatory and manufacturing considerations impacting Flublok’s financial trajectory?

Approved under an FDA license, Flublok has continued to expand its indications:

• 2016: Approved for adults aged 50 and older.
• 2020: Expanded to include adults aged 18-49.

Manufacturing capacity has increased at Sanofi's plant in Indiana, with plans to meet growing demand. Ongoing efforts to secure approvals in additional markets (e.g., Europe, Asia) could diversify revenue streams.

Regulatory hurdles concern new formulations and seasonal updates, requiring continuous clinical evaluations. Delays or denials could influence revenue growth.

What is the financial outlook for Flublok over the next five years?

Sanofi projects a slow but steady increase in Flublok revenues, driven by:

• Expansion into pediatric and high-dose markets
• New formulations incorporating adjuvants
• Growing demand for egg-independent vaccines

From 2022 to 2027, revenue estimates suggest a compound annual growth rate (CAGR) of 5-7%, reaching USD 150-200 million globally in total sales.

Market adoption depends on clinical evidence, competitive pricing, and reimbursement frameworks. The vaccine's niche status limits its market share growth relative to broader influenza vaccine sales.

Summarized key financial indicators:

Indicator	2021	2022 (projected)	2027 (projected)
Estimated global sales	USD 20 million	USD 40 million	USD 150-200 million
Market share	1-2%	2-4%	3-5%
CAGR	N/A	N/A	5-7%

What strategic actions could influence Flublok’s future financial clarity?

• Develop new formulations: Including high-dose or adjuvanted versions.
• Expand geographic coverage: Seek approvals outside North America.
• Engage payers: Increase reimbursement rates and educate providers.
• Invest in clinical research: Demonstrate superior efficacy and safety profiles.

Key Takeaways

Flublok occupies niche segments within the influenza vaccine market, mainly among allergy-sensitive populations. Its growth prospects hinge on increasing global acceptance, regulatory approvals, and competitive positioning. While outperforming traditional egg-based vaccines in specific cohorts, its overall market share remains limited. A targeted approach integrating product diversification and market expansion can enhance its financial trajectory.

FAQs

1. What are the main advantages of Flublok over traditional flu vaccines?
It is egg-free, suitable for individuals with egg allergies, and can be manufactured rapidly, allowing swift response to emerging strains.

2. How does Flublok’s efficacy compare to other influenza vaccines?
Clinical trials indicate comparable or superior immune response, especially in populations with egg allergy sensitivities.

3. What are the market barriers for Flublok?
Higher cost, limited insurance reimbursement, and low physician familiarity restrict broader adoption.

4. Are there upcoming regulatory approvals for Flublok?
Sanofi is pursuing approvals in Europe and Asia; success depends on clinical data and regulatory reviews.

5. What is the potential impact of COVID-19 on Flublok?
COVID-19 awareness accelerates demand for innovative vaccines; recombinant platform might create opportunities for flu vaccine crossover applications.

---

References

[1] MarketsandMarkets. (2022). Influenza Vaccines Market. https://www.marketsandmarkets.com/PressReleases/influenza-vaccine.asp

[2] U.S. Food and Drug Administration. (2013). Flublok FDA approval announcement.

[3] Sanofi. (2022). Annual report and investor presentation.

[4] IQVIA. (2022). Global influenza vaccine sales report.

[5] World Health Organization. (2022). Influenza vaccine coverage and policy updates.